Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 9, 2007, Pages 3535-3541

  Miller, Paul D ^a   Bilezikian, John P ^b   Diaz Curiel, Manuel ^c   Chen, Peiqi ^d   Marin, Fernando ^d   Krege, John H ^d   Wong, Mayme ^d   Marcus, Robert ^d  

^a Health Sciences Center and Colorado Center for Bone Research   (United States)

^b New York Presbyterian Columbia University Medical Center   (United States)

^c Fundacion Jimenez Diaz   (Spain)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; PARATHYROID HORMONE[1-34]; VITAMIN D;

ADULT; ARTICLE; BONE MASS; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERCALCIURIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OSTEOPOROSIS; OUTCOME ASSESSMENT; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 34548762125     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2006-2439     Document Type: Article

References (21)

1. Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, Kendler DL, McClung MR, Miller PD, Olszynski WP, Orwoll E, Yuen CK 2005 Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 26:688-703
2. Juppner H, Kronenberg HM 2003 Parathyroid hormone. In: Favus MJ, ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. 5th ed. Washington, DC: American Society for Bone and Mineral Research; 117-124
3. Bilezikian JP, Silverberg SJ 2003 Primary hyperparathyroidism. In: Favus MJ, ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. 5th ed. Washington, DC: American Society for Bone and Mineral Research; 230-235
4. 2005 FORSTEO Summary of Product Characteristics, Eli Lilly and Co. Ltd, Basingstoke, UK: http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp? documentid=12561
5. Package insert 2004 Eli Lilly and Co. FORTEO. Indianapolis, IN: Eli Lilly and Co.
6. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441
7. Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, Clancy AD, Gaich GA 2003 The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9-17
8. Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, Wagman RB 2005 Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 20:962-970
9. Eastell R, Krege JH, Chen P, Glass EV, Reginster JY 2006 Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin 22:61-66
10. Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore MS, Linda Y, Nold JB 2002 Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 30:312-321
11. Watnick S, Morrison G 2007 Kidney. In: McFee SJ, Papadakis MA, Tierney LM, eds. Current medical diagnosis, treatment. 46th ed. Chap 22. New York: Lange Medical Books/McGraw-Hill, Medical Publishing Division
12. Bushinsky DA 1998 Nephrolithiasis. J Am Soc Nephrol 9:917-924
13. Coe FL, Favus MJ, Crockett T, Strauss AL, Parks JH, Porat A, Gantt CL, Sherwood LM 1982 Effects of low-calcium diet on urine calcium excretion, parathyroid function and serum 1,25(OH)2D3 levels in patients with idiopathic hypercalciuria and in normal subjects. Am J Med 72:25-32
14. Heaney RP, Recker RR, Ryan RA 1999 Urinary calcium in perimenopausal women: normative values. Osteoporos Int 9:13-18
15. Hollander M, Wolfe D 1999 Nonparametric statistical methods. New York: Wiley
16. Conover WJ 1998 Practical nonparametric statistics. New York: Wiley
17. Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH 2005 Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 20:1905-1911
18. Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, Dore RK, Correa-Rotter R, Papaioannou A, Cumming DC, Hodsman AB 2002 A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87:4528-4535
19. Ste-Marie LG, Schwartz SL, Hossain A, Desaiah D, Gaich GA 2006 Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy. J Bone Miner Res 21:283-291
20. Krege JH, Donley DW, Marcus R 2005 Teriparatide, osteoporosis, calcium, and vitamin D. N Engl J Med 353:634-635
21. Miller PD, Bilezikian JP, Deal C, Harris ST, Ci RP 2004 Clinical use of teriparatide in the real world: initial insights. Endocr Pract 10:139-148